Use and Eligibility for Glucose-Like Peptide-1 Receptor Agonist Treatment for Primary Prevention of Stroke
Almost 5 million Americans with diabetes would qualify for GLP-1 use for primary prevention of stroke, but current use among this population is very low.
Authors
- Timothy S. Anderson (ORCID: https://orcid.org/0000-0002-5384-275X)
- Linnea M. Wilson (ORCID: https://orcid.org/0000-0003-2262-1505)
Institutions
- Beth Israel Deaconess Medical Center (US)
- University of Pittsburgh (US)
- VA Pittsburgh Healthcare System (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1212/wnl.0000000000213739
- Primary Topic
- Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00